Healing Effect of Gastric mucosal Lesion of patient with Osteoarthritis or Rheumatism by Cox2-Inhibitor and Anti ulcer agent(Rebamipide) combination therapy.

Healing Effect of Gastric mucosal Lesion of patient with Osteoarthritis or Rheumatism by Cox2-Inhibitor and Anti ulcer agent(Rebamipide) combination therapy. - GLORIA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002112

Enrollment

300

Registered

2009-07-01

Start date

2009-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatic arthritis osteoarthritis lumbago

Interventions

Administration of celecoxib Combined administration of celecoxib and rebamipide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: rheumatic arthritis osteoarthritis lumbago Patient who have either the above-mentioned disease and gave prior written informed consent.

Exclusion criteria

Exclusion criteria: History of gastrointestinal surgery Presence of gastroesophageal reflex disease (GERD) Presence of malignancy Presence of gastrointestinal bleeding or gastrointestinal ulcer Presence of aspirin-induced asthma Pcesence of severe cardiac disorder, renal disorder or liver disorder Impossibility of endoscopic examination Presence of allergy of celecoxib or rebamipide History of percutaneous coronary revascularization Pregnancy and lactation Impossibility of discontinuation of proton pump inhibitor or histamine-2 receptor antagonist Administration of NSAID that excludes aspirin Patient who doctor judged improper

Design outcomes

Primary

Measure	Time frame
An incidence of gastrointestinal bleeding or endoscopic ulcer	—

Countries

Japan

Contacts

Public ContactKyosuke Tanaka

Mie University Hospital Gastroenterology and Hepatology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026